Doylestown, Pennsylvania–(Newsfile Corp. – September 3, 2026) – Mid-Atlantic BioTherapeutics, Inc. (MABT), a pharmaceutical company focused on the clinical development and commercialization of novel therapeutic approaches using AI-enabled technologies, is …
For cancer treatment, aside from surgery for tumor removal and radiation therapy, chemotherapy based on genotoxins (or cytotoxins) using cisplatin/platinum-, taxane- and anthracycline- compounds is the standard of care (SOC). …
Mid-Atlantic BioTherapeutics is pleased to share that Dr. Debanu Das will serve as a panelist in the upcoming event, “Outsourcing Science: How to Choose, Manage, and Learn from CROs and …
Mid-Atlantic BioTherapeutics, Inc. (“MABT”) today announced the acquisition of XPose Therapeutics (“XPose”), a privately held biotechnology company focused on novel precision oncology therapeutics. The acquisition strengthens MABT’s research platform and …
DOYLESTOWN, Pa., Sept. 4, 2024 /PRNewswire/ — Mid-Atlantic BioTherapeutics (MABT) and Accelero Biostructures (Accelero) are pleased to announce a research collaboration to identify novel USP30 inhibitors targeting neurological disorders and other important …
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-gen COVID-19 Vaccine License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, October …
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies COMPANY TO ACQUIRE WORLDWIDE RIGHTS FOR DEVELOPMENT OF IMT504 Boca Raton, FL, Aug. …